Patients
Consecutive patients with obstructive HCM planned for radiofrequency AF
CA between January 2016 and March 2020 were enrolled, and prospectively
studied. Patient demographics, medical history, medications,
echocardiographic data [interventricular septum (IVS) thickness, left
ventricular end-diastolic diameter (LVEDD), LA diameter, LA volume, left
ventricular outflow tract (LVOT) gradient, and left ventricular ejection
fraction (LVEF)], and procedural data were collected in all cases. HCM
patients were propensity score (PS) matched to patients without HCM
(non-HCM) who underwent AF CA, and served as control group.
The diagnosis of HCM was based on 2‐dimensional echocardiography and
defined by a wall thickness ≥15 mm or ≥13mm in patients with a
documented family history of HCM that is not explained by another
cardiac or systemic disease capable of producing the magnitude of
hypertrophy.11 LVOT obstruction was defined as an
outflow tract gradient ≥30 mmHg at rest or during Valsalva maneuver,
standing or exercise.11
The institutional ethics committee approved the study protocol, and
written informed consent was obtained from all patients.